Year: 2020
Type: article
Abstract: Prophylactic vaccines remain the best approach for controlling the human immunodeficiency virus-1 (HIV-1) transmission. Despite the limited efficacy of the RV144 trial in Thailand, there is still no vaccine candidate that has been proven successful. Consequently, great efforts have been made to improve HIV-1 antigens design and discover delivery platforms for optimal immune elicitation. Owing to immunogenic, structural, and functional diversity, virus-like particles (VLPs) could act as efficient vaccine carriers to display HIV-1 immunogens and provide a variety of HIV-1 vaccine development strategies as well as prime-boost regimes. Here, we describe VLP-based HIV-1 vaccine candidates that have been enrolled in HIV-1 clinical trials and summarize current advances and challenges according to preclinical results obtained from five distinct strategies. This mini-review provides multiple perspectives to help in developing new generations of VLP-based HIV-1 vaccine candidates with better capacity to elicit specific anti-HIV immune responses.
Source: Frontiers in Immunology
Authors: Chun-Wei Chen, Narcís Saubi, Joan Joseph-Munné
Language: English
Topic: HIV Research and Treatment
Subfield: Virology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,950
Awards: G1871225350, G2790675217, G3517080532, G3559709381, G434337789, G571882677, European AIDS Vaccine Initiative 2020, G6085964217, Construcción, caracterización y evaluación in vivo de MTBVAC:VIH, cepa recombinante viva atenuada de M.tuberculosis lisina auxotrófica. Vacuna bivalente frente a VIH y Tuberculosis, G7107406481, G7820791223
OpenAlex ID: W3091494080